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Abstract Using a CD4-binding assay to assess the conforma-
tion of the human immunodeficiency virus envelope glycoprotein 
(CHO+ Env), we studied the effect of treatment with various 
glycosidases on the stability of Env in denaturing environments 
and in biological media: cleavage from Env of either high-
mannose-type glycans (HMT Env) by endoglycosidase H or 
sialic acid residues (Sial- Env) by sialidase did not alter Env 
stability whereas its complete deglycosylation (CHO Env) by 
A'-glycanase had a large effect. The influence of glycan removal 
on Env sensitivity to proteases was also studied. Thrombin 
cleavage within V3 was affected by TV-glycanase treatment; both 
HMT Env and CHO Env displayed an increased sensitivity 
to other endoproteases. Thus, partial deglycosylation increases 
Env sensitivity to proteases but only its total deglycosylation 
alters its stability. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The mature human immunodeficiency virus type-1 (HIV-1) 
envelope (Env) is composed of gpl20 and gp41, the cleavage 
products of the gpl60 precursor. At the virus surface, gpl20 
mediates HIV binding to CD4+ cells; gp41 induces the sub-
sequent membrane fusion between HIV and the host cell. 
Parts of gpl20, including its third variable domain (V3), are 
also involved in the fusion process [1]. 
HIV Env is heavily glycosylated; Env from various origins 
presents 15-17 sialylated complex glycans and 6-8 high-man-
nose-type structures (HMT) [2]. Their positions are conserved 
among different isolates and they are evenly distributed along 
the molecule [3]. The current view is that glycosylation is 
required, during biosynthesis, for Env processing, folding 
and expression at the cell surface; in contrast, glycans are 
not necessary for Env function after biosynthesis [4-6]. 
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Env is the primary target for protective antibodies and the 
key component of vaccine trials [7]. Its glycans help HIV to 
escape the immune response and the use of deglycosylated 
gpl60 as an immunogen may overcome this problem, despite 
several drawbacks: (i) mutation of some glycan sites alters the 
Env antigenic conformation but does not uncover epitopes 
[8]; (ii) as suggested [5,9] to explain that small amounts of 
SDS alter CD4 binding to deglycosylated, but not to glycosyl-
ated, Env [9,10], it has been shown that deglycosylation ren-
ders Env susceptible to treatments that alter protein stability 
[11]. The role that each of the two main glycan structures, i.e. 
the complex structures and the HMT, plays in the stability of 
Env under the conditions described previously [11] and in the 
resistance to proteolysis remained to be studied. Here, we 
addressed these points by means of endoglycosidase H 
(EH) treatment to investigate the role of the HMT and desia-
lylation with sialidase (Sial) to study that of sialic acid resi-
dues which are responsible for most of the biological proper-
ties of the complex glycans [12]. Our criteria to study Env 
degradation were its CD4-binding ability — a good marker 
of Env conformation as it requires several domains to form 
the binding site [1] — and polyacrylamide gel electrophoresis 
(PAGE) patterns. 
2. Materials and methods 
2.1. Reagents 
Monoclonal antibody 41a9 (Hybridolab, Paris, France) binds the 
gp41 sequence 605-609. Soluble (s) recombinant gpl60i.ai from BHK-
21 cells [13] was obtained from Transgene S.A. (Strasbourg, France); 
gpl20oB8 from CHO cells was obtained from CAMR (Salisbury, 
UK); sCD4 (a gift from I. Jones, Institute of Virology, Oxford and 
the MRC ADP, UK) was expressed using the baculovirus expression 
system. 
2.2. Labeling procedures 
CD4, gpl20 and gpl60 (5 ug in 40 ul of phosphate buffer, 150 mM 
NaCl, pH 7.4 (PBS)) were labeled with 200 uCi of 125INa in a 4 nM 
iodogen-coated tube for 20 min at 20°C (specific radioactivity: 15 uCi/ 
Jig, irrespective of the antigen), as described in [9], and then purified 
on a PD10 column (Pharmacia, Uppsala, Sweden). 
2.3. Env treatments 
2.3.1. Enzymatic treatments. Labeled (106 cpm/30 (J.1 of PBS final 
volume) or unlabeled (2 u.g/10 ul) glycosylated native (CHO+) Env 
was treated overnight at 37°C as described in [14-16] with (i) type X 
Sial (Boehringer Mannheim, Germany; 20 mU) (Sial-treated mole-
cules are named Sial- thereafter) or (ii) EH (Boehringer; 6 mU) to 
cleave HMT (EH-treated molecules: HMT-) or (iii) A'-glycanase 
(NG; Boehringer; 300 mU) to cleave all W-glycans (NG-treated mol-
ecules: CHO-). Env (2.10° cpm) were treated at 37°C with various 
endoproteinases (Boehringer): (i) Arg C (2-200 mU/30 ul of 0.1 M 
ammonium bicarbonate buffer (ABB), pH 8.5, for 6 h); (ii) Glu C 
(0.04-40 U/30 ul of ABB for 6 h); (iii) pronase (0.02-200 ng/30 ul of 
PBS for 6 h); (iv) bovine thrombin (1.25-125 U/30 ul of ABB for 
18 h). The samples were treated with 5% SDS and 5% P-mercapto-
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Fig. 1. Effect of various treatments on the subsequent CD4 binding of differently glycosylated gpl 60s. After heating at 70°C or incubation in 
2 M guanidine, in human serum or in cell lysate — or no treatment (untreated samples) — the different gpl60s (CHO+-, Sial --, H M T - - and 
CHO~ gpl60) were absorbed onto 41a9-coated wells. After incubation with 125I-labeled CD4, bound radioactivity was counted. 
ethanol at 95°C and the proteins were separated by 10% SDS-PAGE; 
the pattern was scanned with a Phospholmager (Bio-Rad, Les Ullis, 
France). To facilitate scanning and because, despite several gpl60 
purification steps performed by the manufacturer, contaminants 
were detected on gels, the sensitivity to proteases was studied using 
a batch of gpl20 that migrated as a single band and was glycosylated 
like gpl60. 
2.3.2. Incubation of Env in various environments. Labeled (2.10s 
cpm/30 ill of final volume) or unlabeled (2 itg/30 ul) Env preparations 
were (i) subjected for 2 h to 2 M guanidine-HCl and then diluted 
1:100 in PBS-2% casein (PBSC); (ii) heated for 5 min at 70°C in a 
water bath; (iii) incubated for 18 h at 37°C in 50% serum (obtained 
from a healthy donor) or with cell lysate (106 BHK-21 cells (ECAAC, 
Salisbury, UK) cultured in Glasgow medium (Flowbio, Les Ulis, 
France), 5% fetal calf serum, were lysed by three freeze-thaw cycles 
[11]). After dilution (at least 1:5), CD4 binding was tested. To avoid 
interference from albumin, samples incubated with serum were immu-
nopurified with a pool of anti-HIV+ human sera (1:100 dilution) and 
Protein A Sepharose (Pharmacia, Uppsala, Sweden) [14] before SDS-
PAGE. 
2.4. Binding assays 
Wells (Maxisorp; Nunc, Roskild, Denmark) were coated with 41a9 
antibody (1.5 ug/100 ul of 50 mM ABB, pH 9.6) overnight and 
blocked with PBSC. gpl60 was incubated for 2 h at 20°C. After a 
wash, 125I-labeled CD4 (2.104 cpm) was incubated for 2 h. After three 
washes, bound radioactivity was counted [11], The signal in wells from 
which gpl60 was omitted was defined as background. The treatments 
did not modify gpl60 binding to wells as the binding of 125I-label-
edgpl60 to 41a9-coated wells was unchanged after similar treatment 
(not shown). When serum or guanidine was used, gpl60 bound to the 
well was quantified by ELISA with a pool of anti-HIV+ human sera 
(1:100) and anti-human IgG coupled to peroxidase as reported in [15]. 
The figures illustrate a representative experiment (« = 3). 
3. Results 
3.1. CD4-binding ability of differently glycosylated gpl60s 
after incubation under various conditions 
After treatment with glycosidases and incubation in various 
conditions, the CD4 binding of the resulting gpl60 was 
studied using a test in which Env is captured via its gp41 
domain, leaving intact the CD4-binding subunit [11]. 
CHO+ gpl60 and partially (S ia l - gp l60 and 
H M T " gpl60) and fully deglycosylated ( C H O " ) gpl60 
each bound C D 4 in a dose-dependent manner (Fig. 1). 
C H O ~ gp l60 binding was one-third of that of 
CHO+ gpl60, and H M T " gpl60 and Sial" gpl60 pre-
sented intermediate binding capacities. None of the various 
treatments substantially modified the binding of 
CHO+ gpl60, Sial" gpl60 or H M T " gpl60. However, all 
the treatments reduced C H O ~ gpl60 binding to CD4 (Fig. 1). 
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Fig. 2. Sensitivity of differently glycosylated gpl60s to thrombin. The different gpl60s (CHO+-, Sial--, HMT-- and CHO" gpl60) 
treated with thrombin (lane 1, 125 U; lane 2, 42 U; lane 3, 12.5 U; lane 4, 4.2 U; lane 5, 1.25 U; land C, mock treated gpl60). 
Thus, partial deglycosylation did not alter Env stability 
under our conditions. 
3.2. Susceptibility of differently glycosylated gpl60s to 
thrombin 
Native Env is cleaved by thrombin only within V3 [17]. 
Because glycans protect glycoproteins from proteolysis, we 
studied whether deglycosylation of gpl60 allowed cleavage 
by thrombin at sites other than in V3. 
CHO+ gpl60 was treated with thrombin under conditions 
previously reported to cleave Env only at the crown of V3 
[17]. The 160 kDa band visualized by SDS-PAGE was elim-
inated in a thrombin dose-dependent manner (Fig. 2) concom-
itantly with the accumulation of a 90 kDa species also found 
in the control sample, suggesting that a fraction of gpl60 was 
already cleaved in the preparation we used. This 90 kDa form 
corresponds to the previously described C-terminal cleavage 
product [17]. The 70 kDa band was not an env sequence and it 
did not correspond to the N-terminal thrombin cleavage prod-
uct of about 70 kDa [17]: it was found in the controls, it was 
not affected by either thrombin or glycosidase treatments and 
it did not react with anti-HIV+ human sera (not shown). 
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Fig. 3. Sensitivity of differently glycosylated gpl20s to proteases. The different gpl20s (CHO+-, Sial"-, H M T - and CHO" gpl20) were 
treated with either Glu C (A: lane 1, 40 U; lane 2, 4 U; lane 3, 0.4 U; lane 4, 0.04 U) or pronase (B: lane 1, 200 ng; lane 2, 20 ng; lane 3, 
2 ng; lane 4, 0.2 ng; lane 5, 0.02 ng). The amount of radioactivity corresponding to the original species was quantified with a Phosph'olmager 
scanner. (The lane corresponding to the control situation is the 100% signal.) 
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Fig. 4. Effect of biological media on differently glycosylated gpl20s. 
The different gpl20s (CHO+-, Sial"-, H M T - and CHO gpl20) 
were incubated with either serum or cell lysate. Control: gpl20 not 
preincubated in the media. 
Presumably, the expected N-terminal cleavage product was 
not radiolabeled: indeed, non-denaturing labeling labels only 
one or few Tyr residues among the many available on a pro-
tein. Thrombin treatment of Sial - gpl60 (MW of the original 
band: 140 kDa) and HMT" gpl60 (130 kDa) resulted in the 
accumulation of 85 kDa and 80 kDa species, respectively. 
These MW are consistent with the partial deglycosylation of 
the C-terminal fragment. The susceptibility of CHO+ gpl60, 
Sial" gpl60 and HMT" gpl60 to thrombin activity was 
similar (complete degradation with 40 U). gpl60 was com-
pletely deglycosylated under our conditions [9] and resulted 
in a deglycosylated species of about 90 kDa. Thrombin cleav-
age of CHO Env within V3 was expected to give a 55 kDa 
fragment corresponding to the C H O - C-terminal fragment. 
Unexpectedly, C H O - gpl60 was cleaved by 1.25 U of throm-
bin to give a 70 kDa band; thus, cleavage occurred at a site 
other than V3. In the presence of high thrombin doses, the 70 
kDa band was lost and a 30 kDa fragment appeared. 
Thus, partial deglycosylation did not significantly influence 
Env sensitivity to thrombin, whereas total deglycosylation un-
masked new cleavage site(s). 
3.3. Susceptibility of differently glycosylated gpl20s to various 
proteases and to incubation in biological media 
3.3.1. Incubation with proteases. Because deglycosylation 
affected Env cleavage by thrombin, we studied whether gly-
cans protect Env against various other proteases. 
Sial-, EH- or NG-treatment of gpl20 resulted in homoge-
neous bands of 110, 100 and 60 kDa, respectively (Fig. 3). The 
dose of Glu C (Fig. 3A) required to degrade completely Env 
was higher for CHO+ gpl20 and Sial gpl20 than for 
HMT" gpl20; CHO" gpl20 was the most sensitive. The 
gels were scanned: C H O - gpl20 and HMT" gpl20 were 
degraded at 10-fold and 5-fold lower enzyme concentrations, 
respectively, than those required for Sial - gpl20 and 
CHO+ gpl20 digestions. Similarly, treatment of 
CHO+ gpl20 and Sial - gpl20 with the maximum Arg C 
(0.2 U) or Lys C (0.12 U) dose which could be used in our 
test led to a 50% loss of the native band (not shown). These 
doses completely degraded H M T - - and C H O - gpl20. Fi-
nally, the sensitivity of CHO+ gpl20 and Sial - gpl20 to 
pronase was similar whereas the sensitivity of gpl20 was in-
creased by EH- or NG-treatment (Fig. 3B). Similar results 
were obtained with our batch of gpl60 (not shown). 
Thus, the partial deglycosylation of Env altered its resist-
ance to proteases. 
3.3.2. Incubation in serum or in cell lysate. These data 
suggest that the altered CD4 binding of C H O - gpl60 after 
incubation in serum or cell lysate may have been due to pro-
teolysis. This was tested (Fig. 4): incubation in these media 
did not substantially alter the gel pattern of gpl20 other than 
the appearance of minor bands of low MW following 
C H O - gpl20 incubation in cell lysate. Unexpectedly, but 
reproducibly, H M T - gpl20 incubated with serum migrated 
as a 120 kDa band. 
Thus, incubation in biological media did not result in a 
substantial proteolysis of deglycosylated gpl20. 
4. Discussion 
Partial deglycosylation by either EH or a neuraminidase of 
broad specificity [16] diminished by about 20% and 10%, re-
spectively, the MW of gpl20 and gpl60; this is in agreement 
with the nature of the glycans attached to recombinant Env 
from CHO [2,15] or BHK-21 cells [9]. 
As reported for various proteins [18-21], heating or incu-
bation in guanidine altered the conformation of CHO Env. 
In contrast, partial deglycosylation did not affect Env stabil-
ity; as complex glycans are evenly distributed along the pro-
tein [3], it is likely that a limited, homogeneously distributed, 
padding by complex structures is sufficient to preserve Env 
characteristics. The decreased CD4 binding of C H O - gpl60 
after incubation in cell lysate or serum was not due to pro-
teolysis as the incubation in these media did not result in 
substantial cleavage. 
As enhanced sensitivity to proteases after deglycosylation 
has been described [22-24], we studied the effect of partial 
deglycosylation on the sensitivity of Env to thrombin [17]. 
Thrombin-like proteases cleave Env at the crown of V3, a 
domain that presents a single complex glycan attached 10 
amino acid residues upstream from its apex [3]. It has been 
proposed that this cleavage might be necessary for the 
changes in conformation required for membrane fusion [1]. 
Native and partially deglycosylated gpl60 digested by throm-
bin gave SDS-PAGE patterns consistent with cleavage within 
V3. In strong contrast, C H O - Env was cleaved by a small 
amount of thrombin and a fragment that does not result from 
a cleavage within V3 appeared: indeed, its MW is consistent 
either with that of the C-terminal fragment of gpl60 after 
thrombin cleavage at Arg192 or with that of a N-terminal 
fragment of Env cleaved at one of the 28 potential sites in 
the gp41 domain. Furthermore, high thrombin doses gener-
ated a short fragment that resulted either from the cleavage of 
C H O - Env at sites that are not within V3 or from the fur-
ther rapid digestion — at some of its 37 potential cleavage 
sites some of which are likely to be unmasked by deglycosyl-
ation — of the C-terminal fragment generated by the cleavage 
within V3. Thus, glycans restrict thrombin cleavage to V3 in 
vitro. Similarly, the glycans of the coagulation factor V mol-
ecule maintain a conformation required for its functional 
cleavage by thrombin at a single site [25]. 
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E H , but not neuraminidase, treatment increased Env sensi-
tivity to proteases. Thus, either the H M T per se have a spe-
cific role in the protection of Env against proteolysis or the 
removal of 30% of the glycans is sufficient to uncover proteo-
lytic sites and to increase Env sensitivity to proteolysis, this 
latter consequence being more pronounced when all glycans 
are cleaved by N G . The fact that E H treatment exposes sev-
eral proteolytic Glu C sites is consistent with the observation 
that 14/26 Glu residues of gpl20cB8 and 5/6 high mannose 
glycans at conserved positions on Env produced in C H O cells 
[3] are located in the C-terminal fragment. 
In conclusion, limited glycosylation is sufficient to maintain 
the biochemical properties of Env whereas the presence of 
both H M T and complex glycans is necessary for good protec-
tion against proteolysis. Thus, in addition to modifying HIV 
susceptibility to antibody neutralization, changes in HIV gly-
cosylation alter the protection of the viral envelope against 
degradation. 
Acknowledgements: We thank T. Idziorek (CNRS, Lille, France), I. 
Jones (NERC, Oxford, UK), H. Holmes (MRC ADP, Potters Bar, 
UK) and the ANRS (France) for the gift of biological reagents. This 
work was supported by the ANRS (grant to E.F.). 
References 
[1] Moore, J.P., Jameson, B.A., Weiss, R.A., Sattentau, Q. (1993). In 
Viral Fusion Mechanisms, (Bentz, J., ed.) pp. 230-289. CRC 
Press. 
[2] H. Geyer, C. Holschbach, G. Hunsmann, J. Schneider, J Biol 
Chem 263 (1988) 11760-11767. 
[3] C.K. Leonard, M.W. Spellman, L. Riddle, R.J. Harris, J.N. Tho-
mas, T.J. Gregory, J Biol Chem 265 (1990) 10373-10382. 
[4] L. Ratner, AIDS Res Hum Retrovir 8 (1992) 165-173. 
[5] E. Fenouillet, J.C. Gluckman, I. Jones, Trends Biochem Sci 19 
(1994) 65-70. 
[6] E. Fenouillet, I. Jones, In Persp Drug Discovery Design 5 (1996) 
203-231. 
195 
[7] M. Girard, F. Barre-Sinoussi, E. Van Der Ryst, P. Fultz, AIDS 
Res Hum Retrovir 12 (1996) 461^63. 
[8] A. Bolmstedt, S. Sjolander, J.E.S. Hansen, L. Akerblom, A. 
Hemming, S.L. Hu, B. Morein, S. Olofsson, J AIDS 12 (1996) 
213-220. 
[9] E. Fenouillet, B. Clerget, J.C. Gluckman, L. Montagnier, E. 
Bahraoui, J Exp Med 169 (1989) 807-822. 
[10] T.J. Matthews, K.J. Weinhold, H.K. Lyerly, J. Langlois, H. Wig-
zel, D.P. Bolognesi, Proc Natl Acad Sci USA 84 (1987) 5424-
5428. 
[11] M.J. Papandreou, T. Idziorek, R. Miquelis, E. Fenouillet, FEBS 
Lett 379 (1996) 171-176. 
[12] R. Schauer, Trends Biochem Sci 10 (1985) 357-360. 
[13] M.P. Kieny, R. Lathe, Y. Riviere, K. Dott, D. Schmitt, M. 
Girard, L. Montagnier, J.P. Lecocq, Prot Eng 2 (1988) 219-225. 
[14] E. Fenouillet, I.M. Jones, J Gen Virol 76 (1995) 1509-1515. 
[15] E. Fenouillet, R. Miquelis, R. Drillien, Virology 218 (1996) 224-
231. 
[16] A.L. Tarentino, R. Trimble, T.H. Plummer, Meth Cell Biol 32 
(1989) 111-139. 
[17] G. Clements, M. Prices-Jones, P. Stephens, C. Sutton, T. Schultz, 
P. Clapham, J. McKeating, M. McClure, S. Thomson, M. 
Marsh, J. Kay, R. Weiss, J. Moore, AIDS Res Hum Retrovir 
7 (1991) 3-16. 
[18] C. Wang, M. Eufemi, C. Turano, A. Giartosio, Biochemistry 35 
(1996) 7299-7307. 
[19] E. Tsuda, G. Kawanishi, M. Ueda, S. Masuda, R. Sasaki, Eur J 
Biochem 188 (1990) 405-411. 
[20] F.K. Chu, R.B. Trimble, F. Maley, J Biol Chem 253 (1978) 
8691-8693. 
[21] M. Mendonca, G.T. Zancan, Arch Biochem Biophys 266 (1988) 
427^134. 
[22] B.A. Bernard, K.M. Yamada, K. Olden, J Biol Chem 257 (1982) 
8549-8554. 
[23] B.A. Bernard, S.A. Newton, K. Olden, J Biol Chem 258 (1983) 
12198-12202. 
[24] A.B. Federici, J.H. Elder, L. De Marco, Z.M. Ruggeri, S. Zim-
merman, J Clin Invest 74 (1984) 2049-2055. 
[25] T. Bruin, A. Sturk, J. Ten Cate, M. Cath, Eur J Biochem 170 
(1987) 305-310. 
